Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Matsubara Y, Masuishi T, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Bando H, Taniguchi H, Kadowaki S, Ando M, Tajika M, Muro K. Matsubara Y, et al. Among authors: nakazawa t. J Cancer Res Clin Oncol. 2023 Mar;149(3):1123-1129. doi: 10.1007/s00432-022-03979-2. Epub 2022 Mar 22. J Cancer Res Clin Oncol. 2023. PMID: 35314873 Clinical Trial.
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. Matsubara Y, et al. Among authors: nakazawa t. Esophagus. 2023 Jul;20(3):524-532. doi: 10.1007/s10388-022-00978-7. Epub 2023 Jan 3. Esophagus. 2023. PMID: 36595124
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
Ando M, Honda K, Hosoda W, Matsubara Y, Kumanishi R, Nakazawa T, Ogata T, Nakata A, Kodama H, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Muro K. Ando M, et al. Among authors: nakazawa t. Int J Clin Oncol. 2023 May;28(5):644-653. doi: 10.1007/s10147-023-02316-y. Epub 2023 Mar 10. Int J Clin Oncol. 2023. PMID: 36899286 Free PMC article.
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ogata T, Narita Y, Oze I, Kumanishi R, Nakazawa T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Bando H, Taniguchi H, Kadowaki S, Ando M, Ito S, Tajika M, Muro K. Ogata T, et al. Among authors: nakazawa t. Ther Adv Med Oncol. 2024 Feb 9;16:17588359241229428. doi: 10.1177/17588359241229428. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38344409 Free PMC article.
Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study.
Kodama H, Kadowaki S, Nakazawa T, Matsubara Y, Narita Y, Honda K, Masuishi T, Taniguchi H, Ando M, Koide Y, Tachibana H, Kodaira T, Sawabe M, Terada H, Beppu S, Nishikawa D, Suzuki H, Hanai N, Muro K. Kodama H, et al. Among authors: nakazawa t. Anticancer Res. 2024 Mar;44(3):1227-1232. doi: 10.21873/anticanres.16918. Anticancer Res. 2024. PMID: 38423663
2,092 results